Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTG 370: Delavirdine vs Lamivudine with Indinavir in HIV
NCT00000882Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- May 1999
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of delavirdine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of patients with plasma HIV RNA concentration below the limit of detection at 96 weeks. Status: completed.
02
Drugs
delavirdine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000882.